dimethyl (3-cyclohexyl-2-oxopropyl)phosphonate | 53273-28-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: dimethyl (3-cyclohexyl-2-oxopropyl)phosphonate
• 英文别名: dimethyl 2-oxo-3-cyclohexylpropylphosphonate；1-cyclohexyl-3-dimethoxyphosphorylpropan-2-one
• CAS: 53273-28-2
• 化学式: C₁₁H₂₁O₄P
• 分子量: 248.259
• InChiKey: OILPPNKWYFAORW-UHFFFAOYSA-N

物化性质

• 沸点：
  345.5±25.0 °C(Predicted)
• 密度：
  1.091±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  dimethyl (3-cyclohexyl-2-oxopropyl)phosphonate 在 sodium tetrahydroborate 、 N,N-二异丙基乙胺 、 lithium chloride 作用下， 以 乙腈 为溶剂， 生成 7-[(R)-2-((E)-(S)-4-Cyclohexyl-3-hydroxy-but-1-enyl)-5-oxo-pyrrolidin-1-yl]-heptanoic acid ethyl ester
  参考文献：
  名称：

  Lactams as EP4 prostanoid receptor subtype selective agonists. Part 1: 2-Pyrrolidinones-stereochemical and lower side-chain optimization

  摘要：

  A series of 7-[(5R)-substituted 2-oxo-1-pyrrolidinyl]-heptanoic acids were prepared, their isomeric purity determined, and pharmacologically evaluated. Lactams with affinity for the EP4 receptor displayed agonist behavior. The lower side-chain of the lactam template could be substituted to afford ligands (e.g., 17, 24, 30, 31, and 33) of high potency and greater than 1000-fold affinity for EP4 versus the other EP prostanoid receptors. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.01.063
• 作为产物：
  描述：

  环己基乙酸甲酯 、 甲基膦酸二甲酯 在 正丁基锂 、 溶剂黄146 作用下， 以 四氢呋喃 、 正己烷 、 水 为溶剂， 生成 dimethyl (3-cyclohexyl-2-oxopropyl)phosphonate
  参考文献：
  名称：

  2,5,6,7-tetranor-4,8-inter-m-phenylene PGI.sub.2 derivatives

  摘要：

  本文披露了一种展现出优异体内持续时间和活性的新型前列腺素I.sub.2（PGI.sub.2）衍生物，所述衍生物由以下一般式表示：##STR1##其中R.sub.1、X、R.sub.2和R.sub.3如本文所定义。

  公开号：

  US04775692A1

文献信息

• COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE
  申请人：Merck Patent GmbH

  公开号：US20160075711A1

  公开（公告）日：2016-03-17

  The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of IDO, and for the treatment of IDO-related disorders.

  本发明涉及化合物及其药学上可接受的组合物，用作IDO拮抗剂，用于治疗与IDO相关的疾病。
• EP4 receptor selective agonists in the treatment of osteoporosis
  申请人：——

  公开号：US20020065308A1

  公开（公告）日：2002-05-30

  This invention is directed to EP4 receptor selective prostaglandin agonists of the Formula I, 1 wherein R 2 , X, Z and Q are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds. This invention is also directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth in a mammal comprising administering those compounds.

  这项发明针对公式I中的EP4受体选择性前列腺素激动剂，其中R2、X、Z和Q的定义如规范中所述。该发明还涉及含有这些化合物的药物组合物。该发明还涉及治疗低骨密度症状的方法，特别是骨质疏松症、虚弱、骨折、骨缺损、儿童特发性骨量减少、牙槽骨丧失、下颌骨丧失、骨折、骨切开术、与牙周炎相关的骨丧失或哺乳动物体内假体生长中的骨丧失，包括给予这些化合物。
• 15-Substituted-.omega.-pentanorprostaglandins
  申请人：Pfizer Inc.

  公开号：US04152527A1

  公开（公告）日：1979-05-01

  The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.

  本发明涉及用于制备15-取代-.omega.-戊烷基前列腺素的各种中间体。本发明的新型前列腺素已被发现具有与母体前列腺素相当的活性特征，但表现出更大的组织特异性作用。
• Methods of treatment with selective EP4 receptor agonists
  申请人：——

  公开号：US20030207925A1

  公开（公告）日：2003-11-06

  The present invention provides a method of treating hypertension, liver failure, loss of patency of ductus arteriosus, glaucoma or ocular hypertension in a patient, comprising administering to the patient a therapeutically effective amount of a selective EP 4 receptor agonist of Formula I 1 or a prodrug thereof, a pharmaceutically acceptable salt of the selective EP 4 receptor agonist or prodrug or a stereoisomer or diastereomeric mixture of the EP 4 receptor agonist, prodrug or salt, wherein the variables X, Z, Q, , and R 2 are as defined in the specification.

  本发明提供了一种治疗患有高血压、肝功能衰竭、动脉导管未开放、青光眼或眼压增高的患者的方法，包括向患者施用公式I1中的选择性EP4受体激动剂或其前药的治疗有效量、选择性EP4受体激动剂的药学上可接受的盐或前药的盐，或EP4受体激动剂、前药或盐的立体异构体或对映体混合物，其中变量X、Z、Q、和R2如规范所定义。
• Gamma lactams as prostaglandin agonists and use thereof
  申请人：Araldi Luca Gian

  公开号：US20050288357A1

  公开（公告）日：2005-12-29

  1,2-substituted 5-pyrrolidinone compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, renal dysfunction, an immune deficiency disorder, dry eye, ichthyosis, elevated intraocular pressure, sleep disorder, or gastric ulcer, inflammatory disorders and other diseases and disorders associated with the prostaglandin family of compounds.

  本发明提供了1,2-取代的5-吡咯烷酮化合物，并提供了利用或包含一个或多个此类化合物的治疗方法和制药组合物。本发明的化合物可用于各种治疗方案，包括治疗或预防早产、痛经、哮喘、高血压、不孕或生育障碍、不良血液凝固、先兆子痫或子痫、嗜酸性粒细胞异常、性功能障碍、骨质疏松和其他骨骼疾病或障碍、肾功能障碍、免疫缺陷性疾病、干眼症、鱼鳞病、眼内压升高、睡眠障碍或胃溃疡、炎症性疾病和其他与前列腺素类化合物有关的疾病和障碍。